Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
38 hedge funds and large institutions have $167M invested in Karuna Therapeutics, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$38.2M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$34.6M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$22.7M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$15.5M |
| 5 |
Sands Capital Management
Arlington,
Virginia
|
+$11.6M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MS
26
Maven Securities
St Helier,
Jersey
| $501K | +$501K | +25,000 | New |
|
|
FCM
27
Flinton Capital Management
Philadelphia,
Pennsylvania
| $327K | +$410K | +20,468 | New |
|
|
TAM
28
Tyers Asset Management
Austin,
Texas
| $270K | +$337K | +16,856 | New |
|
29
Citigroup
New York
| $230K | +$230K | +11,500 | New |
|
|
NA
30
Neuburgh Advisers
Los Angeles,
California
| $212K | +$265K | +13,244 | New |
|
|
DCM
31
DAFNA Capital Management
Los Angeles,
California
| $200K | +$200K | +10,000 | New |
|
32
Norges Bank
Oslo,
Norway
| $200K | +$200K | +10,000 | New |
|
|
MCIM
33
Meadow Creek Investment Management
Atlanta,
Georgia
| $154K | +$193K | +9,632 | New |
|
|
PIM
34
Partner Investment Management
San Francisco,
California
| $116K | +$145K | +7,219 | New |
|
|
FIA
35
FNY Investment Advisers
New York
| $16K | +$16.2K | +811 | New |
|
|
RCM
36
Riverhead Capital Management
Wilmington,
Delaware
| $10K | +$12.9K | +642 | New |
|
37
Bank of America
Charlotte,
North Carolina
| $9K | +$8.97K | +448 | New |
|
|
CCA
38
Catalyst Capital Advisors
Huntington,
New York
| $6K | +$6.21K | +310 | New |
|
KRTX Hedge Fund Activity: Q2 2019 in Review
38 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q2 2019, worth a combined $167M.
Buyers outnumbered sellers: 38 funds opened new KRTX positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $38.2M.
- 38 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q2 2019, up from 0 in Q1 2019.
- Funds reported $167M of Karuna Therapeutics, Inc. Common Stock stock for Q2 2019.
- 38 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q2 2019 and 0 closed out, a net change of +38 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q2 2019 was Fidelity Investments, an estimated $38.2M added.
Based on aggregated 13F filings for Q2 2019.